PDCD1 and melanoma: Combinations of newly FDA-approved therapies targeting PD-1 and LAG-3 via nivolumab and relatlimab, respectively, have shown improved progression-free survival compared to nivolumab monotherapies among patients with advanced melanoma (n = 30) [56].